BREAKING: FDA accepts for priority review a sBLA application for our investigational antibody-drug conjugate for the treatment of recurrent or metastatic #cervicalcancer, developed with our partner Genmab. Learn more: on.pfizer.com/5703

At #GU24, we’re excited to share new data in genitourinary cancers, including Pfizer’s latest research in prostate & bladder cancer. pfizer.com/news/announcem… #GUCancer #CancerResearch

The EMA has accepted our application for a combination therapy for advanced #UrothelialCancer submitted alongside Astellas Pharma US and Merck. Learn more: on.pfizer.com/3Sz8a2T

.U.S. FDA grants Fast Track designation for our investigational treatment for estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic #breast cancer, in development with our partner Arvinas. Learn more:

BREAKING: We are proud to announce that the European Commission has approved our new oral treatment option for patients 16 years and older with moderately to severely active #UlcerativeColitis. More here: on.pfizer.com/3wnL3kg

Today, we announced positive topline results from a Phase 3 study in people with relapsed or refractory diffuse large B-cell lymphoma #DLBCL. Learn more: on.pfizer.com/49LBSJd

BREAKING: Today, @EU_Comission granted marketing authorization for our 20-valent pneumococcal conjugate vaccine to help provide infants and children with the broadest serotype protection against #PneumococcalDisease. Read more: on.pfizer.com/4abumab

Pfizer is committed to making a difference in the lives of patients living with advanced cervical cancer. Together, with our partner Genmab we will present additional data from our phase 3 study at SGO. More details: on.pfizer.com/43dPmeh

BREAKING: The EU Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for our new antibiotic for the treatment of multidrug-resistant infections. Read more: on.pfizer.com/3TwKwV5

Today, we announced positive top-line data from the Phase 3 study of our respiratory syncytial virus (#RSV) vaccine in adults ages 18-59 with an increased risk for the disease. Learn more: on.pfizer.com/3WauhQD

BREAKING: The European Commission has approved our new antibiotic for the treatment of multidrug-resistant infections caused by Gram-negative bacteria. More here: bit.ly/3xVT2Wj

BREAKING: The FDA has approved Pfizer’s one-time gene therapy for the treatment of eligible adults with #hemophilia B. Read more: on.pfizer.com/3QjgaVc

The FDA grants full approval of our therapy developed with our partner Genmab, for the treatment of recurrent or metastatic #CervicalCancer. Read More About Today’s Announcement: on.pfizer.com/4a0DAFY

We’re at #AUA24, where we’re presenting our latest #ProstateCancer research and connecting with the #urology community, who shares our mission of helping to change patient lives.

Today at #ASCO24 data will be presented from our Phase 3 study evaluating a regimen for the treatment of relapsed or refractory diffuse large B-cell lymphoma (#DLBCL). Learn more about our #bloodcancer research: on.pfizer.com/4aJWZvb

Don’t miss the presentation of the latest hematology data at #ASCO24 including 4-year data for a novel regimen that includes our medicine for advanced classical #Hodgkinlymphoma. Learn more about these data: on.pfizer.com/3V4uTF8

Today we announced positive top-line data from a Phase 3 study evaluating our investigational gene therapy treatment for adults with moderately severe to severe #hemophilia A. Learn more here: on.pfizer.com/46l1lIn Sangamo Therapeutics

BREAKING: The European Commission has approved our one-time gene therapy for eligible adults with #hemophilia B. Read more: on.pfizer.com/4cXxQPo